DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,993 filers reported holding DANAHER CORPORATION in Q3 2022. The put-call ratio across all filers is 1.00 and the average weighting 0.7%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $656,473 | +3.4% | 2,646 | 0.0% | 0.04% | -5.0% |
| Q2 2023 | $635,040 | -6.8% | 2,646 | -2.1% | 0.04% | -21.6% |
| Q1 2023 | $681,012 | -91.0% | 2,702 | -90.6% | 0.05% | -77.9% |
| Q4 2022 | $7,590,481 | +4.3% | 28,598 | +1.5% | 0.23% | +10.5% |
| Q3 2022 | $7,279,000 | +24.2% | 28,182 | +21.9% | 0.21% | +16.1% |
| Q2 2022 | $5,863,000 | -52.9% | 23,125 | -45.5% | 0.18% | -45.8% |
| Q1 2022 | $12,445,000 | -18.5% | 42,426 | -8.6% | 0.33% | +13.7% |
| Q4 2021 | $15,272,000 | +151.2% | 46,418 | +132.5% | 0.29% | +16.3% |
| Q3 2021 | $6,079,000 | +4.7% | 19,967 | -7.7% | 0.25% | +28.7% |
| Q2 2021 | $5,804,000 | +11.6% | 21,629 | -6.4% | 0.20% | +19.6% |
| Q1 2021 | $5,201,000 | +12.4% | 23,106 | +10.9% | 0.16% | +13.2% |
| Q4 2020 | $4,629,000 | +0.2% | 20,837 | -2.9% | 0.14% | -4.0% |
| Q3 2020 | $4,620,000 | +7.3% | 21,457 | -11.9% | 0.15% | +1.4% |
| Q2 2020 | $4,307,000 | +19.8% | 24,359 | -6.2% | 0.15% | +5.0% |
| Q1 2020 | $3,595,000 | -60.3% | 25,976 | -56.0% | 0.14% | -14.0% |
| Q4 2019 | $9,054,000 | +6.2% | 58,994 | -0.0% | 0.16% | +11.6% |
| Q3 2019 | $8,522,000 | +1.1% | 59,002 | +0.1% | 0.15% | -2.0% |
| Q2 2019 | $8,426,000 | +24.8% | 58,958 | +15.3% | 0.15% | -17.6% |
| Q1 2019 | $6,753,000 | +27.2% | 51,153 | -0.6% | 0.18% | +4.6% |
| Q4 2018 | $5,309,000 | -47.6% | 51,486 | -60.2% | 0.17% | -75.7% |
| Q3 2016 | $10,135,000 | -7.6% | 129,293 | +19.1% | 0.72% | -0.3% |
| Q2 2016 | $10,964,000 | -24.0% | 108,554 | -28.6% | 0.72% | -42.4% |
| Q1 2016 | $14,430,000 | +21.4% | 152,119 | +18.8% | 1.24% | +9.9% |
| Q4 2015 | $11,890,000 | +365.4% | 128,019 | +327.0% | 1.13% | +330.4% |
| Q3 2015 | $2,555,000 | +36.2% | 29,983 | +36.8% | 0.26% | +57.5% |
| Q2 2015 | $1,876,000 | -78.9% | 21,915 | -79.1% | 0.17% | -77.6% |
| Q1 2015 | $8,910,000 | +79.3% | 104,945 | +81.0% | 0.75% | +95.8% |
| Q4 2014 | $4,970,000 | -58.6% | 57,984 | -63.3% | 0.38% | -30.2% |
| Q3 2014 | $12,004,000 | -57.6% | 157,994 | -56.0% | 0.55% | -28.6% |
| Q2 2014 | $28,283,000 | +1079.4% | 359,236 | +1023.6% | 0.76% | +893.5% |
| Q1 2014 | $2,398,000 | – | 31,972 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |